Navigation Links
Shawn Cross Joins Burrill Merchant Banking
Date:6/18/2009

SAN FRANCISCO, June 18 /PRNewswire/ -- Burrill & Company, a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media, is pleased to announce that Shawn Cross has joined the firm as Managing Director, Merchant Banking. Shawn will assist clients in structuring and completing mergers and acquisitions, partnering and capital raising transactions. In addition, Shawn will make an important contribution to the collective efforts of the Burrill Merchant Banking Team in the formation and deployment of Burrill Private Equity funds. Shawn brings considerable experience in life science investment banking including:

- A twelve year career beginning at Alex. Brown & Sons Inc. where he focused on growth oriented companies and completed a broad range of transactions for leading life sciences companies such as Sepracor and United Therapeutics.

- Six years in London and New York City predominantly focused on mid and large-cap pharmaceutical companies - after Alex. Brown was acquired by Deutsche Bank AG in 1999 - including strategic advisory assignments for numerous European pharmaceutical companies such as Bayer AG in addition to book-running successful financings for emerging US companies such as Auxilium Pharmaceuticals and Sciele.

- An exclusive focus on growth-oriented life sciences companies at Thomas Weisel Partners LLC in San Francisco.

Mr. Cross received an MBA with Honors from Columbia Business School. Prior to business school, he was involved in cancer research at the University of Washington Medical School where his research on the role of p53 and solid tumor progression culminated with a first authorship in the journal Science.

"We are delighted to have Shawn on board," said G. Steven Burrill, CEO of Burrill & Company. "Given the turmoil in the capital markets and in investment banking, we see an enormous opportunity to serve the life sciences industry by accelerating the growth of our Merchant Banking business. Shawn's experience in life science investment banking is a perfect fit with our ongoing global life sciences activities."

"The strategy to combine M&A, partnering and capital raising advisory services with the deployment of our own private equity and venture capital provides unique value to the marketplace," said James Watson, Head of Merchant Banking at Burrill & Company. "Shawn joins our rapidly growing team and will considerably enhance our capabilities."

About Burrill Merchant Banking

Burrill Merchant Banking assists life science companies to identify, negotiate and close strategic transactions. Service lines include:

- Merger & Acquisitions

- Strategic Partnering

- Spin-Outs and Divestitures

- Financing Advisory and Private Placement

- Private Equity

About Burrill & Company

Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the monthly Burrill Report, which tracks the progress of the global biotechnology industry and our annual "State of the Industry" report, the latest of which is Biotech 2009-Life Sciences: Navigating the Sea Change, the 23rd annual report on the industry. The 470-plus page book contains analysis and perspectives on the performance of the industry in 2008 and projections for 2009 and beyond. www.burrillandco.com


'/>"/>
SOURCE Burrill & Company
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
2. EFT BioTech Holdings, Inc.s Subsidiary Receives First Permit to Cross Taiwan Strait
3. Thomson Reuters Commemorates World IP Week with Series of Strategic Intellectual Property Seminars Across the U.S.
4. Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008
5. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
6. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
7. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
8. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
9. From Race Cars and Google Doodles to Day Spas and Night Lights: Groups Across the U.S. Prepare to Join World Diabetes Day Celebrations on November 14
10. American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC
11. Cantel Medical Announces Management Succession at Crosstex Healthcare Disposables Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):